Maxim Group analyst Naz Rahman reiterated a Buy rating on Assertio Therapeutics yesterday and set a price target of $3.00.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Naz Rahman has given his Buy rating due to a combination of factors that highlight Assertio Therapeutics’ potential for growth. One of the primary reasons is the promising data on Sympazan, a core growth driver for the company, which was presented at a significant medical conference. This data provides insights into patient profiles and the benefits of switching to Sympazan from other treatments, particularly for Lennox-Gastaut Syndrome (LGS), a severe form of epilepsy.
Furthermore, Sympazan, being the only FDA-approved oral film formulation of clobazam, offers a unique advantage for patients, especially children who have difficulty swallowing pills. The study’s findings suggest that Sympazan can be effectively targeted to the right patient demographics, potentially increasing its adoption among physicians. Additionally, the company’s other assets, such as Rolvedon, are contributing to stable revenue streams, while the impact of Indocin going generic is diminishing. These factors combined suggest a positive outlook for Assertio’s financial performance, justifying the Buy rating.
In another report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $3.00 price target.